Generic placeholder image

Combinatorial Chemistry & High Throughput Screening


ISSN (Print): 1386-2073
ISSN (Online): 1875-5402

Clinical Trial

Role of Ischemia Modified Albumin Serum Levels as an Oxidative Stress Marker in Children with Diabetic Ketoacidosis

Author(s): Mutlu U. Yazıcı*, Ganime Ayar, Senay Savas-Erdeve, Ebru Azapağası, Salim Neşelioğlu, Özcan Erel and Semra Çetinkaya

Volume 22, Issue 8, 2019

Page: [577 - 581] Pages: 5

DOI: 10.2174/1386207322666191008214919

Price: $65


Aim and Objective: Ischemia modified albumin (IMA) is a biomarker that has been introduced recently for use in the evaluation of oxidative stress. The aim of this study was to measure the ischemia modified albumin serum levels in pediatric patients with diabetic ketoacidosis (DKA) during acidosis and after the patient recovered from acidosis and to compare these with the control group.

Materials and Methods: Pediatric patients with Type I diabetes mellitus (T1DM) who were admitted to the pediatric intensive care unit with the diabetic ketoacidosis were assigned as the study group and healthy children who were admitted to the outpatient clinic and decided as healthy after clinic and laboratory evaluation were selected as the control group. IMA and adjusted IMA levels were evaluated in the blood samples from the control group and the study group when admitted first time to the intensive care unit during the acidosis period (DKA before treatment, DKA-BT), and after recovering from acidosis (DKA after treatment, DKA-AT).

Results: A total of 24 pediatric patients with diabetic ketoacidosis and 30 healthy control children matching age and sex were included in the current study. The albumin levels in pediatric patients with T1DM during DKA-BT were higher than the albumin levels after acidosis (4.101±0.373, 3.854±0.369 g/dL, respectively) (p<0.05). However, there was no significant difference when these values were compared to the control group. Mean values of IMA and Adj-IMA were statistically higher in DKAAT compared to the control group (0.748±0.150 vs 0.591±0.099, p< 0.001; 0.708±0.125 vs 0.607±0.824, p< 0.001, respectively). IMA and adjusted IMA levels measured after recovered from acidosis were significantly higher compared to the level of IMA during DKA (0.748±0.150 vs 0.606±0.105 as absorbance unit, p<0.001; 0.708±0.125 vs 0.625±0.100, p<0.05, respectively).

Conclusion: In children with T1DM, even though acidosis recovered following the treatment in diabetic ketoacidosis, which is an oxidative stress marker, the ischemia modified albumin levels and adjusted ischemia modified albumin levels were high.

Keywords: Children, diabetic ketoacidosis, Ischemia modified albumin, oxidative stress, treatment, serum level.

« Previous
Liese, A.D.; D’Agostino, R.B., Jr; Hamman, R.F.; Kilgo, P.D.; Lawrence, J.M.; Liu, L.L.; Loots, B.; Linder, B.; Marcovina, S.; Rodriguez, B.; Standiford, D.; Williams, D.E. SEARCH for Diabetes in Youth Study Group. The burden of diabetes mellitus among US youth: Prevalence estimates from the SEARCH for Diabetes in Youth Study. Pediatrics, 2006, 118(4), 1510-1518.
[] [PMID: 17015542]
Patterson, C.C.; Dahlquist, G.G.; Gyürüs, E.; Green, A.; Soltész, G. EURODIAB Study Group. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: A multicentre prospective registration study. Lancet, 2009, 373(9680), 2027-2033.
[] [PMID: 19481249]
Agrawal, S.; Baird, G.L.; Quintos, J.B.; Reinert, S.E.; Gopalakrishnan, G.; Boney, C.M.; Topor, L.S. Pediatric diabetic ketoacidosis with hyperosmolarity: Clinical characteristics and outcomes. Endocr. Pract., 2018, 24(8), 726-732.
[] [PMID: 30084686]
Fayfman, M.; Pasquel, F.J.; Umpierrez, G.E. Management of hyperglycemic crises: Diabetic ketoacidosis and hyperglycemic hyperosmolar state. Med. Clin. North Am., 2017, 101(3), 587-606.
[] [PMID: 28372715]
Zeitler, P.; Haqq, A.; Rosenbloom, A.; Glaser, N. Drugs and therapeutics committee of the lawson wilkins pediatric endocrine society. Hyperglycemic hyperosmolar syndrome in children: pathophysiological considerations and suggested guidelines for treatment. J. Pediatr., 2011, 158(1), 9-14. 14.e1-14.e2
[] [PMID: 21035820]
Ceriello, A. Acute hyperglycaemia and oxidative stress generation. Diabet. Med., 1997, 14(Suppl. 3), S45-S49.
[<S45: AID-DIA444>3.3.CO;2-I] [PMID: 9272613]
Anraku, M.; Yamasaki, K.; Maruyama, T.; Kragh-Hansen, U.; Otagiri, M. Effect of oxidative stress on the structure and function of human serum albumin. Pharm. Res., 2001, 18(5), 632-639.
[] [PMID: 11465418]
Coverdale, J.P.C.; Katundu, K.G.H.; Sobczak, A.I.S.; Arya, S.; Blindauer, C.A.; Stewart, A.J. Ischemia-modified albumin: Crosstalk between fatty acid and cobalt binding. Prostaglandins Leukot. Essent. Fatty Acids, 2018, 135, 147-157.
[] [PMID: 30103926]
Wudkowska, A.; Goch, J.; Goch, A. Ischemia-modified albumin in differential diagnosis of acute coronary syndrome without ST elevation and unstable angina pectoris. Kardiol. Pol., 2010, 68(4), 431-437.
[PMID: 20425705]
Hjortshøj, S.; Kristensen, S.R.; Ravkilde, J. Diagnostic value of ischemia-modified albumin in patients with suspected acute coronary syndrome. Am. J. Emerg. Med., 2010, 28(2), 170-176.
[] [PMID: 20159386]
Quiles, J.; Roy, D.; Gaze, D.; Garrido, I.P.; Avanzas, P.; Sinha, M.; Kaski, J.C. Relation of ischemia-modified albumin (IMA) levels following elective angioplasty for stable angina pectoris to duration of balloon-induced myocardial ischemia. Am. J. Cardiol., 2003, 92(3), 322-324.
[] [PMID: 12888145]
Sinha, M.K.; Gaze, D.C.; Tippins, J.R.; Collinson, P.O.; Kaski, J.C. Ischemia modified albumin is a sensitive marker of myocardial ischemia after percutaneous coronary intervention. Circulation, 2003, 107(19), 2403-2405.
[] [PMID: 12742986]
Erdem, S.S.; Yerlikaya, F.H.; Çiçekler, H.; Gül, M. Association between ischemia-modified albumin, homocysteine, vitamin B(12) and folic acid in patients with severe sepsis. Clin. Chem. Lab. Med., 2012, 50(8), 1417-1421.
[] [PMID: 22868807]
Dogru, M.; Akoglu, H.; Kilinckaya, M.F.; Ulfer, G. Ischemia-modified albumin levels in children with asthma: a pilot study. Arch. Argent. Pediatr., 2018, 116(4), e522-e528.
[PMID: 30016026]
Shahramian, I.; Bazi, A.; Sargazi, A. An overview of celiac disease in childhood type 1 diabetes. Int. J. Endocrinol. Metab., 2018, 16(3)e66801
[] [PMID: 30214462]
Wolfsdorf, J.I.; Glaser, N.; Agus, M.; Fritsch, M.; Hanas, R.; Rewers, A.; Sperling, M.A.; Codner, E. ISPAD clinical practice consensus guidelines 2018: Diabetic ketoacidosis and the hyperglycemic hyperosmolar state. Pediatr. Diabetes, 2018, 19(27), 155-177.
[] [PMID: 29900641]
Bar-Or, D.; Lau, E.; Winkler, J.V. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia-a preliminary report. J. Emerg. Med., 2000, 19(4), 311-315.
[] [PMID: 11074321]
Lippi, G.; Montagnana, M.; Salvagno, G.L.; Guidi, G.C. Standardization of ischemia-modified albumin testing: Adjustment for serum albumin. Clin. Chem. Lab. Med., 2007, 45(2), 261-262.
[] [PMID: 17311519]
Rodrigues, R.; de Medeiros, L.A.; Cunha, L.M.; Garrote-Filho, M.D.S.; Bernardino Neto, M.; Jorge, P.T.; Resende, E.S.; Penha-Silva, N. Correlations of the glycemic variability with oxidative stress and erythrocytes membrane stability in patients with type 1 diabetes under intensive treatment. Diabetes Res. Clin. Pract., 2018, 144, 153-160.
[] [PMID: 29427698]
Vantyghem, M.C.; Balduyck, M.; Zerimech, F.; Martin, A.; Douillard, C.; Bans, S.; Degand, P.M.; Lefebvre, J. Oxidative markers in diabetic ketoacidosis. J. Endocrinol. Invest., 2000, 23(11), 732-736.
[] [PMID: 11194706]
Talwalkar, S.S.; Bon Homme, M.; Miller, J.J.; Elin, R.J. Ischemia modified albumin, a marker of acute ischemic events: A pilot study. Ann. Clin. Lab. Sci., 2008, 38(2), 132-137.
[PMID: 18469358]
Lippi, G.; Montagnana, M. Ischemia-modified albumin in ischemic disorders. Ann. Thorac. Cardiovasc. Surg., 2009, 15(2), 137.
[PMID: 19471231]
Sbarouni, E.; Georgiadou, P.; Voudris, V. Ischemia modified albumin changes - review and clinical implications. Clin. Chem. Lab. Med., 2011, 49(2), 177-184.
[] [PMID: 21083441]
Gulpamuk, B.; Tekin, K.; Sonmez, K.; Inanc, M.; Neselioglu, S.; Erel, O.; Yilmazbas, P. The significance of thiol/disulfide homeostasis and ischemia-modified albumin levels to assess the oxidative stress in patients with different stages of diabetes mellitus. Scand. J. Clin. Lab. Invest., 2018, 78(1-2), 136-142.
[] [PMID: 29298534]
Ma, S.G.; Jin, Y.; Xu, W.; Hu, W.; Bai, F.; Wu, X.J. Increased serum levels of ischemia-modified albumin and C-reactive protein in type 1 diabetes patients with ketoacidosis. Endocrine, 2012, 42(3), 570-576.
[] [PMID: 22437883]
Guerin-Dubourg, A.; Cournot, M.; Planesse, C.; Debussche, X.; Meilhac, O.; Rondeau, P.; Bourdon, E. Association between fluorescent advanced glycation end-products and vascular complications in type 2 diabetic patients. BioMed Res. Int., 2017, 20177989180
[] [PMID: 29362717]
Ghosh, K.; Muddeshwar, M.G.; Ghosh, K. Ischemia modified albumin test to detect early diabetic complications. Am. J. Med. Sci., 2017, 354(5), 467-470.
[] [PMID: 29173357]
Sowjanya, U.V.P.U.; Sridevi, C.; Rajkumari, R.D.M.M.; Kasibabu, A. Study of ischemia modified albumin in type 2 diabetes as a marker of severity. IOSR Journal of Dental and Medical Sciences, 2015, 14(12), 14-17.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy